HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G’s Mielle Acquisition, John Legend’s Loved01, And A Concealer For Hiding Hickeys; Beauty News In Brief

Executive Summary

Textured hair-care specialist Mielle Organics will continue to be led by wife-and-husband duo Monique and Melvin Rodriguez within Procter & Gamble’s Beauty division, pending regulatory approval. More beauty M&A and product launch news.

You may also be interested in...

Toying With Metaverse Marketing? BUXOM Cosmetics Opens Virtual Club In Decentraland

BUXOM Cosmetics has a go at marketing in the metaverse, launching PlumpVerse in Decentraland, a virtual reality platform powered by the Ethereum blockchain where users can purchase digital LAND to build and monetize content and applications.

Target Corporation Settles ‘Oil-Free’ Cosmetic Suit; Walmart And L’Oreal Next In Line

Putative class actions filed in recent years against leading beauty companies and retailers for alleged false and misleading “oil-free” claims on cosmetic products appear to be drawing to a close, more often than not via undisclosed settlements.

California DTSC Begins Taking Notifications Of Nail Products Containing Toluene

Effective 1 January, Nail Products Containing Toluene are the latest Priority Product adopted under California’s Safer Consumer Products regulation, requiring notifications from responsible entities by 2 March or 60 days after affected products enter the market. Alternatives analysis work will follow for companies that do not reformulate or discontinue products, among other options.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts